Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/RPL23A_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/RPL23A_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/RPL23A_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/RPL23A_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/RPL23A_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/RPL23A_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/RPL23A_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/RPL23A_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/RPL23A_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/RPL23A_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/RPL23A_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/RPL23A_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/RPL23A_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000002725 | Oral cavity | EOLP | ribosomal large subunit assembly | 9/2218 | 27/18723 | 2.88e-03 | 1.70e-02 | 9 |
GO:000218134 | Oral cavity | NEOLP | cytoplasmic translation | 102/2005 | 148/18723 | 3.70e-64 | 2.20e-60 | 102 |
GO:007182634 | Oral cavity | NEOLP | ribonucleoprotein complex subunit organization | 60/2005 | 227/18723 | 1.98e-11 | 2.81e-09 | 60 |
GO:002261834 | Oral cavity | NEOLP | ribonucleoprotein complex assembly | 57/2005 | 220/18723 | 1.46e-10 | 1.43e-08 | 57 |
GO:002261333 | Oral cavity | NEOLP | ribonucleoprotein complex biogenesis | 93/2005 | 463/18723 | 1.34e-09 | 9.49e-08 | 93 |
GO:004225534 | Oral cavity | NEOLP | ribosome assembly | 21/2005 | 61/18723 | 6.65e-07 | 1.93e-05 | 21 |
GO:004227334 | Oral cavity | NEOLP | ribosomal large subunit biogenesis | 21/2005 | 72/18723 | 1.32e-05 | 2.36e-04 | 21 |
GO:004225433 | Oral cavity | NEOLP | ribosome biogenesis | 55/2005 | 299/18723 | 4.32e-05 | 6.10e-04 | 55 |
GO:000002734 | Oral cavity | NEOLP | ribosomal large subunit assembly | 9/2005 | 27/18723 | 1.41e-03 | 1.01e-02 | 9 |
GO:000218118 | Prostate | BPH | cytoplasmic translation | 115/3107 | 148/18723 | 1.08e-60 | 6.68e-57 | 115 |
GO:002261318 | Prostate | BPH | ribonucleoprotein complex biogenesis | 150/3107 | 463/18723 | 2.18e-17 | 5.62e-15 | 150 |
GO:007182618 | Prostate | BPH | ribonucleoprotein complex subunit organization | 87/3107 | 227/18723 | 2.63e-15 | 4.07e-13 | 87 |
GO:002261818 | Prostate | BPH | ribonucleoprotein complex assembly | 85/3107 | 220/18723 | 3.16e-15 | 4.55e-13 | 85 |
GO:004225418 | Prostate | BPH | ribosome biogenesis | 90/3107 | 299/18723 | 3.82e-09 | 1.44e-07 | 90 |
GO:004227318 | Prostate | BPH | ribosomal large subunit biogenesis | 33/3107 | 72/18723 | 6.29e-09 | 2.25e-07 | 33 |
GO:004225518 | Prostate | BPH | ribosome assembly | 29/3107 | 61/18723 | 1.86e-08 | 5.75e-07 | 29 |
GO:000002718 | Prostate | BPH | ribosomal large subunit assembly | 12/3107 | 27/18723 | 6.34e-04 | 4.32e-03 | 12 |
GO:000218119 | Prostate | Tumor | cytoplasmic translation | 115/3246 | 148/18723 | 1.36e-58 | 8.43e-55 | 115 |
GO:002261319 | Prostate | Tumor | ribonucleoprotein complex biogenesis | 159/3246 | 463/18723 | 3.17e-19 | 1.52e-16 | 159 |
GO:007182619 | Prostate | Tumor | ribonucleoprotein complex subunit organization | 91/3246 | 227/18723 | 3.62e-16 | 7.50e-14 | 91 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0301018 | Breast | Precancer | Ribosome | 80/684 | 167/8465 | 7.33e-44 | 2.32e-41 | 1.77e-41 | 80 |
hsa0517118 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
hsa0301019 | Breast | Precancer | Ribosome | 80/684 | 167/8465 | 7.33e-44 | 2.32e-41 | 1.77e-41 | 80 |
hsa0517119 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
hsa0301024 | Breast | IDC | Ribosome | 83/867 | 167/8465 | 6.07e-39 | 9.87e-37 | 7.38e-37 | 83 |
hsa0517124 | Breast | IDC | Coronavirus disease - COVID-19 | 86/867 | 232/8465 | 1.50e-28 | 9.72e-27 | 7.27e-27 | 86 |
hsa0301034 | Breast | IDC | Ribosome | 83/867 | 167/8465 | 6.07e-39 | 9.87e-37 | 7.38e-37 | 83 |
hsa0517134 | Breast | IDC | Coronavirus disease - COVID-19 | 86/867 | 232/8465 | 1.50e-28 | 9.72e-27 | 7.27e-27 | 86 |
hsa0301044 | Breast | DCIS | Ribosome | 82/846 | 167/8465 | 8.69e-39 | 1.40e-36 | 1.03e-36 | 82 |
hsa0517144 | Breast | DCIS | Coronavirus disease - COVID-19 | 86/846 | 232/8465 | 2.42e-29 | 1.56e-27 | 1.15e-27 | 86 |
hsa0301054 | Breast | DCIS | Ribosome | 82/846 | 167/8465 | 8.69e-39 | 1.40e-36 | 1.03e-36 | 82 |
hsa0517154 | Breast | DCIS | Coronavirus disease - COVID-19 | 86/846 | 232/8465 | 2.42e-29 | 1.56e-27 | 1.15e-27 | 86 |
hsa0517120 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
hsa0301020 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
hsa05171110 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
hsa03010110 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
hsa0301025 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
hsa0517125 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
hsa0301035 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
hsa0517135 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RPL23A | SNV | Missense_Mutation | novel | c.131N>T | p.Pro44Leu | p.P44L | P62750 | protein_coding | tolerated(0.15) | benign(0.104) | TCGA-PL-A8LV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
RPL23A | insertion | Frame_Shift_Ins | novel | c.173_174insA | p.Lys59GlnfsTer14 | p.K59Qfs*14 | P62750 | protein_coding | | | TCGA-A8-A08G-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
RPL23A | insertion | Frame_Shift_Ins | novel | c.174_175insGCACGAAAAAG | p.Lys59AlafsTer27 | p.K59Afs*27 | P62750 | protein_coding | | | TCGA-A8-A08G-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
RPL23A | SNV | Missense_Mutation | | c.121C>T | p.Arg41Cys | p.R41C | P62750 | protein_coding | tolerated(0.1) | benign(0.117) | TCGA-A5-A0VQ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD |
RPL23A | SNV | Missense_Mutation | rs758296129 | c.119N>C | p.Ile40Thr | p.I40T | P62750 | protein_coding | tolerated(0.07) | benign(0.219) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RPL23A | SNV | Missense_Mutation | | c.224N>A | p.Ala75Asp | p.A75D | P62750 | protein_coding | deleterious(0.04) | benign(0.364) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RPL23A | SNV | Missense_Mutation | novel | c.75G>T | p.Lys25Asn | p.K25N | P62750 | protein_coding | deleterious(0.03) | probably_damaging(0.987) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
RPL23A | SNV | Missense_Mutation | novel | c.239N>T | p.Pro80Leu | p.P80L | P62750 | protein_coding | deleterious(0.05) | possibly_damaging(0.537) | TCGA-EC-A24G-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
RPL23A | SNV | Missense_Mutation | novel | c.111G>T | p.Lys37Asn | p.K37N | P62750 | protein_coding | deleterious(0.04) | possibly_damaging(0.904) | TCGA-EO-A3AY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
RPL23A | SNV | Missense_Mutation | rs760295259 | c.106A>G | p.Lys36Glu | p.K36E | P62750 | protein_coding | tolerated(0.05) | benign(0.16) | TCGA-EO-A3KX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |